MetaCap

ImageneBio (IMA) vs OKYO Pharma (OKYO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImageneBio (IMA) has outperformed OKYO Pharma (OKYO) over the past year, losing 44.9% versus a loss of 49.5%. OKYO Pharma is the larger company by market cap ($56.2 million vs $48.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMA-44.87%OKYO-49.53%
+52%-4%-60%
Nov 21, 20251 yearNov 20, 2026
IMA-90.85%OKYO-64.33%
+115%+6%-102%
May 16, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMA versus OKYO key metrics
MetricIMAOKYO
Share price$3.92$1.07
Market cap$48.83M$56.15M
1-day change0.00%-7.76%
YTD return-43.19%-48.31%
1-year return-44.87%-49.53%
5-year return-97.86%—
EPS (TTM)$-2.11$-0.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$800.00K—
Revenue growth (YoY)-77.14%—
Net income (latest FY)$-45.35M$-4.71M
Operating margin-6056.38%—
Net margin-5668.63%—
52-week high$7.60$3.20
52-week low$3.00$1.00
Distance from 52-week high-48.42%-66.56%
Analyst consensusnonestrong_buy
Avg. price target upside+359.18%+678.50%
Average volume15.86K143.41K
Shares outstanding12.46M52.48M
Employees185
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ImageneBio

IMA stock →

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

About OKYO Pharma

OKYO stock →

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

IMA vs OKYO FAQ

Which is bigger, ImageneBio or OKYO Pharma?

OKYO Pharma (OKYO) is larger, with a market capitalization of $56.15M compared with $48.83M for ImageneBio (IMA).

Which stock has performed better over the past year, IMA or OKYO?

IMA returned -44.87% over the past 12 months, compared with -49.53% for OKYO (price return, excluding dividends). Past performance does not predict future results.

Are ImageneBio and OKYO Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons